IL106459A - Nitrogen mustard based prodrugs, process for their preparation and pharmaceutical compositions thereof particularly in combination with carboxypeptidase g2-a5b7 antibody conjugates for cancer therapy - Google Patents

Nitrogen mustard based prodrugs, process for their preparation and pharmaceutical compositions thereof particularly in combination with carboxypeptidase g2-a5b7 antibody conjugates for cancer therapy

Info

Publication number
IL106459A
IL106459A IL106459A IL10645993A IL106459A IL 106459 A IL106459 A IL 106459A IL 106459 A IL106459 A IL 106459A IL 10645993 A IL10645993 A IL 10645993A IL 106459 A IL106459 A IL 106459A
Authority
IL
Israel
Prior art keywords
compound
vas
formula
bis
group
Prior art date
Application number
IL106459A
Other languages
English (en)
Other versions
IL106459A0 (en
Original Assignee
Zeneca Limited And Cancer Rese
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929215636A external-priority patent/GB9215636D0/en
Priority claimed from GB939310884A external-priority patent/GB9310884D0/en
Application filed by Zeneca Limited And Cancer Rese filed Critical Zeneca Limited And Cancer Rese
Publication of IL106459A0 publication Critical patent/IL106459A0/xx
Publication of IL106459A publication Critical patent/IL106459A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/54—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Seasonings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
IL106459A 1992-07-23 1993-07-22 Nitrogen mustard based prodrugs, process for their preparation and pharmaceutical compositions thereof particularly in combination with carboxypeptidase g2-a5b7 antibody conjugates for cancer therapy IL106459A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929215636A GB9215636D0 (en) 1992-07-23 1992-07-23 Chemical compounds
GB939310884A GB9310884D0 (en) 1993-05-26 1993-05-26 Chemical compounds

Publications (2)

Publication Number Publication Date
IL106459A0 IL106459A0 (en) 1994-11-11
IL106459A true IL106459A (en) 1998-02-08

Family

ID=26301303

Family Applications (1)

Application Number Title Priority Date Filing Date
IL106459A IL106459A (en) 1992-07-23 1993-07-22 Nitrogen mustard based prodrugs, process for their preparation and pharmaceutical compositions thereof particularly in combination with carboxypeptidase g2-a5b7 antibody conjugates for cancer therapy

Country Status (24)

Country Link
US (6) US5405990A (de)
EP (1) EP0651740B1 (de)
JP (1) JP3541037B2 (de)
KR (1) KR100268654B1 (de)
AT (1) ATE172450T1 (de)
AU (1) AU681349B2 (de)
CA (1) CA2101104C (de)
CZ (1) CZ287028B6 (de)
DE (1) DE69321729T2 (de)
DK (1) DK0651740T3 (de)
ES (1) ES2123662T3 (de)
FI (1) FI115048B (de)
GB (1) GB9314960D0 (de)
HU (1) HUT69288A (de)
IL (1) IL106459A (de)
MY (1) MY111635A (de)
NZ (1) NZ254864A (de)
PH (1) PH30004A (de)
PL (1) PL174617B1 (de)
RU (1) RU2129542C1 (de)
SK (1) SK281338B6 (de)
TW (1) TW272971B (de)
WO (1) WO1994002450A1 (de)
ZW (1) ZW9293A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9314960D0 (en) 1992-07-23 1993-09-01 Zeneca Ltd Chemical compounds
CA2167153A1 (en) * 1993-07-15 1995-01-26 Caroline Joy Springer Prodrugs of protein tyrosine kinase inhibitors
GB9315494D0 (en) * 1993-07-27 1993-09-08 Springer Caroline Improvements relating to prodrugs
GB9415167D0 (en) 1994-07-27 1994-09-14 Springer Caroline J Improvements relating to cancer therapy
GB9426133D0 (en) * 1994-12-23 1995-02-22 Zeneca Ltd Chemical compounds
GB9501052D0 (en) 1995-01-19 1995-03-08 Cancer Res Campaign Tech Improvements relating to prodrugs
GB9510830D0 (en) * 1995-05-27 1995-07-19 Zeneca Ltd Proteins
GB9517001D0 (en) * 1995-08-18 1995-10-18 Denny William Enediyne compounds
GB9516943D0 (en) * 1995-08-18 1995-10-18 Cancer Soc Auckland Div Nz Inc Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
US6130237A (en) * 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
US6962702B2 (en) 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
CA2328614C (en) 1999-02-12 2012-06-26 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
GB9907414D0 (en) 1999-03-31 1999-05-26 Cancer Res Campaign Tech Improvements relating to prodrugs
US6765019B1 (en) 1999-05-06 2004-07-20 University Of Kentucky Research Foundation Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
GB0001653D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Uk Ltd Chemical compound
AU2001253479A1 (en) 2000-04-13 2001-10-30 Sts Biopolymers, Inc. Targeted therapeutic agent release devices and methods of making and using the same
US6656718B2 (en) 2000-07-07 2003-12-02 Cancer Research Technology Limited Modified carboxypeptidase enzymes and their use
EP1303481A1 (de) * 2000-07-26 2003-04-23 Patrick Anthony Riley Phenylethylamin-derivate und ihre anwendung in der behandlung von melanomen
RU2181261C1 (ru) * 2000-10-27 2002-04-20 Кировская государственная медицинская академия Способ определения контактной поверхности тупого твердого предмета при ударе по волосистой части головы
RU2177718C1 (ru) * 2000-10-27 2002-01-10 Кировская государственная медицинская академия Способ установления факта удара тупым твердым предметом по волосистой части головы через тканый и нетканый материал
GB0102239D0 (en) 2001-01-29 2001-03-14 Cancer Res Ventures Ltd Methods of chemical synthisis
KR20030033007A (ko) * 2001-05-31 2003-04-26 코울터 파머수티컬, 인코포레이티드 세포독소, 약물전구체, 링커 및 이에 유용한 안정화제
RU2231063C2 (ru) * 2001-10-04 2004-06-20 Войсковая часть 61469 Способ оценки проницаемости иприта через защитные материалы
JP2005516011A (ja) * 2001-12-13 2005-06-02 ランバクシー ラボラトリーズ リミテッド 結晶二水化セフニディールカリウム
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
DE60335383D1 (de) 2002-07-15 2011-01-27 Univ Texas Antikörper mit bindung an anionische phospholipide und aminophospholipide und ihre verwendung bei der behandlung von virusinfektionen
US20040092735A1 (en) * 2002-11-08 2004-05-13 Orchid Chemicals & Pharmaceuticals Limited Process for the preparation of cefuroxime sodium
WO2005000795A2 (en) * 2003-06-10 2005-01-06 Smithkline Beecham Corporation Aniline derivatived androgen-, glucocorticoid-, mineralcorticoid- and progesterone- receptor modulators
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗ｃｄ１９抗体
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
US7691962B2 (en) * 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
BRPI0510909A2 (pt) * 2004-05-19 2008-12-16 Medarex Inc composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
EA016577B1 (ru) * 2005-09-26 2012-06-29 Медарекс, Инк. Конъюгаты антитело-лекарство и их применение
BRPI0619331A2 (pt) 2005-10-26 2011-09-27 Medarex Inc método para fazer um composto para preparar um análogo de cbi cc-1065, método para preparar um análogo de cbi cc-1065 e composto
WO2007059404A2 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
SG177168A1 (en) 2006-12-01 2012-01-30 Medarex Inc Human antibodies that bind cd22 and uses thereof
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
US20100150950A1 (en) 2006-12-14 2010-06-17 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
TWI412367B (zh) 2006-12-28 2013-10-21 梅達雷克斯有限責任公司 化學鏈接劑與可裂解基質以及其之綴合物
JP2010519310A (ja) 2007-02-21 2010-06-03 メダレックス インコーポレイテッド 単一のアミノ酸を有する化学リンカーおよびその複合体
WO2009060198A1 (en) 2007-11-09 2009-05-14 Peregrine Pharmaceuticals, Inc. Anti-vegf antibody compositions and methods
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
JP6417421B2 (ja) 2014-02-28 2018-11-07 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 荷電連結体及び共役体のためのその使用
CA2991973C (en) 2015-07-12 2021-12-07 Suzhou M-Conj Biotech Co., Ltd. Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
KR20220147719A (ko) 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
TW201900606A (zh) * 2017-05-15 2019-01-01 日商旭化成股份有限公司 異氰酸酯的製造方法
WO2019006464A1 (en) 2017-06-30 2019-01-03 Memorial Sloan Kettering Cancer Center COMPOSITIONS AND METHODS OF ADOPTIVE CELLULAR THERAPY AGAINST CANCER
CN113845448B (zh) * 2021-10-20 2023-07-07 厦门大学 一种放射性18f标记化合物及其应用
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
WO2026143022A1 (en) 2024-12-23 2026-07-02 Point Loma Nazarene University Antibody directed enzyme pro-drug therapy (adept) for cancer treatment using an antibody or fragment that binds to a cd206 receptor and 3-cyclopentyl-alpha-phenylalanine-methotrexate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
GB8820850D0 (en) * 1988-09-05 1988-10-05 Cancer Res Campaign Tech Improvements relating to pro-drugs
GB8920011D0 (en) * 1989-09-05 1989-10-18 Mann J New route of synthesis for tertiary butyl esters
JP4115514B2 (ja) * 1991-10-23 2008-07-09 キャンサー・リサーチ・キヤンペーン・テクノロジー・リミテツド Ｃｂ １９５４およびその類似体を細胞障害性の形態に還元するための細菌のニトロリダクターゼ
GB9314960D0 (en) * 1992-07-23 1993-09-01 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
ZW9293A1 (en) 1994-03-30
FI950230A0 (fi) 1995-01-19
HU9500145D0 (en) 1995-03-28
NZ254864A (en) 1996-11-26
MY111635A (en) 2000-10-31
US6277880B1 (en) 2001-08-21
KR100268654B1 (ko) 2000-10-16
DE69321729T2 (de) 1999-03-18
IL106459A0 (en) 1994-11-11
WO1994002450A1 (en) 1994-02-03
ATE172450T1 (de) 1998-11-15
JPH07509461A (ja) 1995-10-19
FI950230L (fi) 1995-01-19
US5660829A (en) 1997-08-26
EP0651740B1 (de) 1998-10-21
US5587161A (en) 1996-12-24
JP3541037B2 (ja) 2004-07-07
US5405990A (en) 1995-04-11
RU95105246A (ru) 1997-04-27
CZ287028B6 (en) 2000-08-16
RU2129542C1 (ru) 1999-04-27
PH30004A (en) 1996-10-29
SK6995A3 (en) 1995-07-11
CA2101104A1 (en) 1994-01-24
GB9314960D0 (en) 1993-09-01
CA2101104C (en) 2007-01-23
SK281338B6 (sk) 2001-02-12
HUT69288A (en) 1995-09-28
US5714148A (en) 1998-02-03
DE69321729D1 (de) 1998-11-26
CZ15195A3 (en) 1995-11-15
AU681349B2 (en) 1997-08-28
TW272971B (de) 1996-03-21
US5958971A (en) 1999-09-28
AU4715693A (en) 1994-02-14
DK0651740T3 (da) 1999-06-28
HK1002683A1 (en) 1998-09-11
EP0651740A1 (de) 1995-05-10
ES2123662T3 (es) 1999-01-16
PL174617B1 (pl) 1998-08-31
PL307226A1 (en) 1995-05-15
FI115048B (fi) 2005-02-28

Similar Documents

Publication Publication Date Title
US5714148A (en) Chemical compounds
US7250439B2 (en) Matrix metalloproteinase inhibitors
JP5840492B2 (ja) アリール−フェニル−スルホンアミド−フェニレン化合物とその使用
EP0380144B1 (de) Verfahren zur Herstellung von optisch aktiven Benzolsulfonamidderivaten
JPH085848B2 (ja) カルボン酸エステル誘導体
JPS63253061A (ja) チオールプロテアーゼ阻害剤としてのアリールオキシおよびアリールアシルオキシメチルケトン
PL188012B1 (pl) Pochodne benzamidyny, sposób wytwarzania pochodnych benzamidyny i ich zastosowanie jako środki lecznicze
AU666342B2 (en) Nitroaniline derivatives and their use as antitumor agents
RU2228330C2 (ru) Омега-амиды n-арилсульфонил-аминокислот
CA2237016A1 (en) Azahexane derivatives as substrate isosters of retroviral asparate proteases
JPH07330761A (ja) 置換クロマン類
US5387707A (en) Route of synthesis for tertiary alkyl esters
WO1990002729A1 (en) Improvements relating to the production of prodrugs
HK1002683B (en) Amino acid linked nitrogen mustard derivatives and their use as prodrugs in the treatment of tumours
CZ31297A3 (en) Pharmaceutical composition for inhibiting leukotrien biosynthesis and the use of urea derivative for preparing such pharmaceutical composition
JPH0480890B2 (de)
JPH0859588A (ja) Ｄ−β−リジルメタンジアミン誘導体、およびそれらの製法
CS208109B2 (en) Method of preparation of the new n-/tetrazol-5-yl/-prostaglandicarboxamids

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees